Onward Medical N.V./ADR
No SEC Form 4 filings for $ONWRF in the last 30 days.
See all $ONWRF insider activity →ONWARD Medical (ONWRF) began its EIGER study, the first implant of the ARC-IM System for chronic spinal cord injury (SCI) patients. The study, with up to 12 participants, aims to assess safety and preliminary effectiveness in restoring mobility. The first procedure was performed in Switzerland. ONWRF's stock is up 2.67%, trading at EUR 2.49.
Groundbreaking procedures extend ONWARD's leadership in the rapidly emerging brain-computer interface ( BCI ) field ARC-BCI Therapy is designed to restore thought-driven movement after spinal cord injury and other movement disabilities
Sponsored Level 1 ADR program facilitates trading by US investors following recent FDA clearance and commercial launch
Over the past 7 days, alphai's AI scored 1 news story mentioning ONWRF (Onward Medical N.V./ADR). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ONWRF coverage spans financial news and technology.
The implantation marks a key milestone that could de‑risk the program and support future funding.
Groundbreaking procedures extend ONWARD's leadership in the rapidly emerging brain-computer interface ( BCI ) field ARC-BCI Therapy is designed to restore thought-driven movement after spinal cord injury and other movement disabilities
The US ADR program is likely to enhance liquidity and investor access, supporting a potential positive price response.
The inclusion of ONWARD Medical N.V. (OTC:ONWRF) on OTCQX is a positive development, likely to improve liquidity and investor access. The sentiment from the market is somewhat bullish, with a sentiment score of 'somewhat-bullish'.
alphai scores every news story that mentions ONWRF with an AI model for sentiment and relevance, and aggregates insider trades from Onward Medical N.V./ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
ONWARD Medical (ONWRF) began its EIGER study, the first implant of the ARC-IM System for chronic spinal cord injury (SCI) patients. The study, with up to 12 participants, aims to assess safety and preliminary effectiveness in restoring mobility. The first procedure was performed in Switzerland. ONWRF's stock is up 2.67%, trading at EUR 2.49.
2 min readGroundbreaking procedures extend ONWARD's leadership in the rapidly emerging brain-computer interface ( BCI ) field ARC-BCI Therapy is designed to restore thought-driven movement after spinal cord injury and other movement disabilities
2 min readSponsored Level 1 ADR program facilitates trading by US investors following recent FDA clearance and commercial launch
2 min readNEW YORK, April 23, 2025 ( GLOBE NEWSWIRE ) -- OTC Markets Group Inc.
2 min read
